Osteoporosis Therapy in Postmenopausal Women With High Risk of Fracture

被引：26
|
作者：
Cappola, Anne R. [1 ]
Shoback, Dolores M. [2 ]
机构：
[1] Univ Penn, Perelman Sch Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA
[2] Univ Calif San Francisco, San Francisco Dept Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94143 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2016年 / 316卷 / 07期
关键词：
D O I：
10.1001/jama.2016.11032
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：715 / 716
页数：2
相关论文
共 50 条
  • [31] Teriparatide therapy and risk of hypercalciuria in postmenopausal women with osteoporosis.
    Miller, P.
    Bilezikian, J.
    Chen, P.
    Marin, F.
    Krege, J.
    Wong, M.
    Marcus, R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S299 - S299
  • [32] Underuse of osteoporosis treatment in postmenopausal women at high risk for low trauma fracture: Evidence from national osteoporosis risk assessment (NORA).
    Siris, ES
    Weiss, TW
    Barlas, S
    Chen, Y
    Barrett-Connor, E
    Miller, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S380 - S380
  • [33] Hormone replacement therapy in the management of postmenopausal osteoporosis and prevention of fracture risk
    Ribot, Claude
    Tremollieres, Florence
    PRESSE MEDICALE, 2006, 35 (10): : 1557 - 1563
  • [34] Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture
    Saag, Kenneth G.
    Williams, Setareh A.
    Wang, Yamei
    Weiss, Richard J.
    Cauley, Jane A.
    CLINICAL THERAPEUTICS, 2020, 42 (06) : 1099 - +
  • [35] Targeted High-Intensity Exercise With And Without Osteoporosis Medications To Reduce Fracture Risk In Postmenopausal Women
    Kistler-Fischbacher, Melanie
    Yong, Jedidah S.
    Weeks, Benjamin K.
    Beck, Belinda R.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2021, 53 (08): : 111 - 112
  • [36] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    E. Söreskog
    I. Lindberg
    J.A. Kanis
    K.E. Åkesson
    D. Willems
    M. Lorentzon
    O. Ström
    P. Berling
    F. Borgström
    Osteoporosis International, 2021, 32 : 585 - 594
  • [37] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    Soreskog, E.
    Lindberg, I.
    Kanis, J. A.
    Akesson, K. E.
    Willems, D.
    Lorentzon, M.
    Strom, O.
    Berling, P.
    Borgstrom, F.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (03) : 585 - 594
  • [38] FRACTURE OCCURRENCE AMONG POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Ngo, J. D.
    Sunarso, S.
    Li-Yu, J. T.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : S710 - S710
  • [39] Romosozumab for the treatment of postmenopausal women at high risk of fracture
    Geusens, Piet
    Appelman-Dijkstra, Natasha
    Lems, Willem
    van den Bergh, Joop
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (01) : 11 - 19
  • [40] Low self-awareness of osteoporosis and fracture risk among postmenopausal women
    Langer, Felipe Welter
    da Silveira Codevilla, Antonio Aurelio
    Dal Osto, Leo Canterle
    Sanchez Campos, Thabara Renaty
    Martins, Tamires Tolazzi
    Barin, Ana Elize
    Rigo, Pietro Hagamenon
    Boufleuer, Natalia Diel
    Santinon, Sheyla Fabiane
    Kipper, Kaira
    Rodrigues, Juliano
    Premaor, Melissa Orlandin
    ARCHIVES OF OSTEOPOROSIS, 2016, 11 (01)
12345